Solid Q3 2017 performance in line with full-year ambitions: Net sales $364.0 million (+7% actual, +7% CER); adjusted net sales $364.4 million (+8% actual, +7% CER vs. +7% CER guidance) EPS $0.21; adjusted EPS $0.32 ($0.32 CER), adjusted EPS excluding restructuring charge $0.32 ($0.32 CER vs. $0.32-0.33 CER guidance) Nine-month 2017 free cash flow of... Read more
OCT 30 2017 Trusted QIAGEN partners can now increase their speed to market by leveraging the company’s industry expertise, world-class manufacturing and thousands of product formulations Beverly, Mass., October 30, 2017 – QIAGEN today announced the launch of its Custom Solutions business, extending its commitment to providing life sciences and molecular diagnostics companies with the... Read more
Trusted QIAGEN partners can now increase their speed to market by leveraging the company’s industry expertise, world-class manufacturing and thousands of product formulations Beverly, Mass., October 30, 2017 – QIAGEN today announced the launch of its Custom Solutions business, extending its commitment to providing life sciences and molecular diagnostics companies with the tools and expertise... Read more
The Hague, 24 October 2017 – The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow created in collaboration with QIAGEN N.V. for ICMP’s missing persons DNA identification laboratory in The Hague. The solution integrates QIAGEN’s GeneReader NGS System and spans all aspects of the DNA laboratory workflow, from... Read more
The Hague, 24 October 2017 – The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow created in collaboration with QIAGEN N.V. for ICMP’s missing persons DNA identification laboratory in The Hague. The solution integrates QIAGEN’s GeneReader NGS System and spans all aspects of the DNA laboratory workflow, from... Read more
Orlando, Florida, Germantown, Maryland, and Hilden, Germany, October 19, 2017 — QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company. In an evaluation, Counsyl — an early QCI adopter — found that it reduced the... Read more
Hilden, Germany, and Germantown, Maryland, October 12, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing (NGS) technologies to bioinformatics solutions for research and clinical testing, figure prominently in independent studies presented this week at the American Society of Human Genetics (ASHG) annual... Read more
Aiding the analysis of hereditary disorders by integrating genomic and clinical databases Hilden and Rostock, Germany, and Germantown, Maryland, October 09, 2017 –QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases.... Read more
Hilden and Rostock, Germany, and Germantown, Maryland, October 09, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into... Read more
Germantown, Maryland, and Hilden, Germany, October 5, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug... Read more